Advertisement

Endocrine

pp 1–7 | Cite as

Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas

  • Marco Losa
  • Pietro Mortini
  • Angela Pagnano
  • Mario Detomas
  • Maria Francesca Cassarino
  • Francesca Pecori Giraldi
Endocrine Surgery
  • 93 Downloads

Abstract

Purpose

somatic mutations in the ubiquitin-specific protease 8 (USP8) gene have recently been described in patients with Cushing’s disease (CD). The aim of the study is to verify whether USP8 mutation may predict early and late outcome of pituitary surgery in patients with CD operated at a single institution.

Methods

We performed a retrospective genetic analysis of 92 adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas. Specimens were screened for USP8 hotspot mutations in the exon 14 with Sanger sequencing. Hormonal and surgical data were compared between USP8 variant carriers and wild-type tumors.

Results

USP8 variants were detected in 22 adenomas (23.9%) with higher prevalence in women (28.9% vs. 5.3% in men; p < 0.05). No significant difference in hormonal levels and tumoral features in relation to USP8 status was observed. Interestingly, USP8-variant carriers were more likely to achieve surgical remission than wild-type adenomas (100% vs. 75.7%; p = 0.01). Conversely, recurrence of CD occurred in 23% of USP8-mutated patients and in 13% of patients with wild-type adenoma. The recurrence-free survival did not differ significantly between the two groups (p = 0.42).

Conclusions

ACTH-secreting pituitary adenomas carrying somatic USP8 mutations are associated with a greater likelihood of surgical remission in patients operated by a single neurosurgeon. Recurrence rates are not related with USP8-variant status.

Keywords

Pituitary neoplasms Pituitary surgery Adrenocorticotropin Cortisol 

Notes

Funding

This research did not receive any specific grant from any agency in the public, commercial or not-for-profit sector.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

References

  1. 1.
    O.M. Dekkers, E. Horvath-Puho, J.O. Jørgensen, S.C. Cannegieter, V. Ehrenstein, J.P. Vandenbroucke et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277–2284 (2013)CrossRefGoogle Scholar
  2. 2.
    L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage et al. Treatment of Cushing’s syndrome: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 2807–2831 (2015)CrossRefGoogle Scholar
  3. 3.
    D. Bochicchio, M. Losa, M. Buchfelder, Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J. Clin. Endocrinol. Metab. 80, 3114–3120 (1995)PubMedGoogle Scholar
  4. 4.
    B.M. Hofman, M. Hlavac, R. Martinez, M. Buchfelder, O.A. Muller, R. Fahlbusch, Long-term results after microsurgery for Cushing’s disease: experience with 426 primary operations over 35 years. J. Neurosurg. 108, 9–18 (2008)CrossRefGoogle Scholar
  5. 5.
    W.F. Chandler, A.L. Barkan, T. Hollon, A. Sakharova, J. Sack, B. Brahma et al. Outcome of transsphenoidal surgery for Cushing disease: a single–center experience over 32 years. Neurosurgery 78, 216–223 (2016)CrossRefGoogle Scholar
  6. 6.
    R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing’s disease. Endocr. Rev. 36, 385–486 (2015)CrossRefGoogle Scholar
  7. 7.
    M. Losa, R. Bianchi, R. Barzaghi, M. Giovanelli, P. Mortini, Persistent ACTH response to desmopressin in the early postoperative period is a risk factor for recurrence of Cushing’s disease. J. Clin. Endocrinol. Metab. 94, 3322–3328 (2009)CrossRefGoogle Scholar
  8. 8.
    S. Melmed, Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol. 7, 257–266 (2011)CrossRefGoogle Scholar
  9. 9.
    S. Sbiera, T. Deutschbein, I. Weigand, M. Reincke, M. Fassnacht, B. Allolio, The new molecular landscape of Cushing’s disease. Trends Endocrinol. Metab. 26, 573–583 (2015)CrossRefGoogle Scholar
  10. 10.
    C.A. Stratakis, Diagnosis and clinical genetics of Cushing syndrome in pediatrics. Endocrinol. Metab. Clin. North. Am. 45, 311–328 (2016)CrossRefGoogle Scholar
  11. 11.
    A. Albani, M. Theodoropoulou, M. Reincke, Genetics of Cushing’s disease. Clin. Endocrinol. (Oxf.). 88, 3–12 (2018)CrossRefGoogle Scholar
  12. 12.
    Z.Y. Ma, Z.J. Song, J.H. Chen, Y.F. Wang, S.Q. Li, L.F. Zhou et al. Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res. 25, 306–317 (2015)CrossRefGoogle Scholar
  13. 13.
    M. Reincke, S. Sbiera, A. Hayakawa, M. Theodoropoulou, A. Osswald, F. Beuschlein et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat. Genet. 47, 31–38 (2015)CrossRefGoogle Scholar
  14. 14.
    L.G. Pérez-Rivas, M. Theodoropoulou, F. Ferraù, C. Nusser, K. Kawaguchi, C.A. Stratakis et al. The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing’s disease. J. Clin. Endocrinol. Metab. 100, E997–E1004 (2015)CrossRefGoogle Scholar
  15. 15.
    K. Hayashi, N. Inoshita, K. Kawaguchi, A. Ibrahim Ardisasmita, H. Suzuki, N. Fukuhara et al. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing’s disease. Eur. J. Endocrinol. 174, 213–226 (2016)CrossRefGoogle Scholar
  16. 16.
    F.R. Faucz, A. Tirosh, C. Tatsi, A. Berthon, L.C. Hernandez-Ramirez, N. Settas et al. Somatic USP8 gene mutations are a common cause of pediatric Cushing disease. J. Clin. Endocrinol. Metab. 102, 2836–2843 (2017)CrossRefGoogle Scholar
  17. 17.
    M. Theodoropoulou, T. Arzberger, Y. Gruebler, M.L. Jaffrain-Rea, J. Schlegel, L. Schaaf et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J. Endocrinol. 183, 385–394 (2004)CrossRefGoogle Scholar
  18. 18.
    H. Fukuoka, O. Cooper, A. Ben-Shlomo, A. Mamelak, S.G. Ren, D. Bruyette et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J. Clin. Invest. 121, 4712–4721 (2011)CrossRefGoogle Scholar
  19. 19.
    M. Losa, P. Mortini, S. Dylgjeri, R. Barzaghi, A. Franzin, C. Mandelli et al. Desmopressin stimulation test before and after pituitary surgery in patients with Cushing’s disease. Clin. Endocrinol. (Oxf.). 55, 61–68 (2001)CrossRefGoogle Scholar
  20. 20.
    M.F. Cassarino, A.G. Ambrogio, A. Cassarino, M.R. Terreni, D. Gentilini, A. Sesta et al. Gene expression profiling in human corticotrope tumors reveals distinct, neuroendocrine profiles. J. Neuroendocrinol. 30, e12628 (2018)CrossRefGoogle Scholar
  21. 21.
    M.F. Cassarino, A. Sesta, L. Pagliardini, M. Losa, G. Lasio, F. Cavagnini et al. Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas. Endocrine 55, 853–860 (2017)CrossRefGoogle Scholar
  22. 22.
    F. Pecori Giraldi, L. Pagliardini, M.F. Cassarino, M. Losa, G. Lasio, F. Cavagnini, Responses to corticotrophin-releasing hormone and dexamethasone in a large series of human adrenocorticotrophic hormone-secreting pituitary adenomas in vitro reveal manifold corticotroph tumoural phenotypes. J. Neuroendocrinol. 23, 1214–1221 (2011)CrossRefGoogle Scholar
  23. 23.
    M. Ravo, M. Mutarelli, L. Ferraro, O.M. Grober, O. Paris, R. Tarallo et al. Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab. Invest. 88, 430–440 (2008)CrossRefGoogle Scholar
  24. 24.
    C. Ballmann, A. Thiel, H.E. Korah, A.C. Reis, W. Saeger, S. Stepanow et al. USP8 mutations in pituitary Cushing adenomas – targeted analysis by next-generation sequencing. J. Endocr. Soc. 2, 266–278 (2018)CrossRefGoogle Scholar
  25. 25.
    L.G. Pérez-Rivas, M. Theodoropoulou, T.H. Puar, J. Fazel, M.R. Stieg, F. Ferraù et al. Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson’s tumor. Eur. J. Endocrinol. 178, 59–65 (2018)CrossRefGoogle Scholar
  26. 26.
    A., Albani, L.G., Pérez-Rivas, C., Dimopoulou, S., Zopp, P., Colon-Bolea, S., Roeber, et al. The USP8 mutational status may predict long-term remission in patients with Cushing’s disease. Clin. Endocrinol. (Oxf). (2018).  https://doi.org/10.1111/cen.13802 CrossRefGoogle Scholar
  27. 27.
    S.S. Chaidarun, B. Swearingen, J.M. Alexander, Differential expression of estrogen receptor-ß (ER ß) in human pituitary tumors: functional interactions with ER α and a tumor-specific splice variant. J. Clin. Endocrinol. Metab. 83, 3308–3315 (1998)PubMedGoogle Scholar
  28. 28.
    S. Oomizu, J. Honda, S. Takeuchi, T. Kakeya, T. Masui, S. Takahashi, Transforming growth factor-α stimulates proliferation of mammotrophs and corticotrophs in the mouse pituitary. J. Endocrinol. 165, 493–501 (2000)CrossRefGoogle Scholar
  29. 29.
    F.F. Casanueva, A.L. Barkan, M. Buchfelder, A. Klibanski, E.R. Laws, J.S. Loeffler et al. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a Pituitary Society statement. Pituitary 20, 489–498 (2017)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pituitary Unit of the Division of Neurosurgery, IRCCS San RaffaeleUniversity Vita-SaluteMilanItaly
  2. 2.Istituto Auxologico Italiano IRCCSNeuroendocrine Research LaboratoryMilanItaly
  3. 3.Department of Clinical Sciences & Community HealthUniversity of MilanMilanItaly

Personalised recommendations